ArticlemSphere2025
Dual use and gain-of-function research: a significant endeavor with biosecurity imperatives.
Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current U.S. administration has recently proposed a pause on all domestic gain-of-function (GoF) research in order to fully revise existing policy. However, domestic controls on GoF research cannot mandate that other nations follow suit and thus do not prohibit non-compliant nations from engaging in such work. In fact, such national constraints may facilitate opportunities for competitor and adversarial nations (and non-state actors) to advance efforts in this space toward nefarious applications. Moreover, certain groups may argue that GoF research may be necessary for advancing biomedical science (A. Casadevall, F. C. Fang, and M. J. Imperiale, mSphere 9:e00714-23, 2024, https://doi.org/10.1128/msphere.00714-23) and global health security and, through this stance, conduct GoF research that has direct dual-use viability. In this light, we argue that all GoF research should be conducted under a robust framework of enhanced BSL controls that explicitly define its dual usability, classify any such enterprise as DURC, engage regulatory oversight, and establish ethical responsibility within the scope and tenor of international law. This essay describes the possible burdens and risks of GoF research, and in addressing the challenges posed by such work, proposes recommendations for future policy toward sustaining beneficial outcomes and preventing or mitigating threats to public health and global biosecurity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.